title: When the clinical trials raise more questions than answers: blood pressure controversy beyond the TRANSCEND results.
authors.affiliation: Department of Cardiology, Hospital Ramón y Cajal, Madrid, Spain. vbarriosa@meditex.es
authors.forename: Vivencio
authors.initials: V
authors.lastname: Barrios
authors.forename: Carlos
authors.initials: C
authors.lastname: Escobar
authors.forename: Rocio
authors.initials: R
authors.lastname: Echarri
authors.forename: Alberto
authors.initials: A
authors.lastname: Calderon
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents